So as yet still quiet here. But I’m sure the guys & girls in the lab are hard at It processing Janssen’s completed clinical trial bloods & here is another reason why they should be offered overtime:
The competion to Janssen, AstraZeneca too are looking at increased indications on top of BGL control in type 2 diabetes with their new oral hypoglycaemic drug, so preventing renal and cardiovascular disease also.
https://www.fiercepharma.com/marketing/astrazeneca-new-awareness-campaign-points-up-cardio-and-renal-risks-associated-type-2
A bit of light reading & food for thought, have a great weekend all
So as yet still quiet here. But I’m sure the guys & girls in the...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
29.0¢ |
Change
-0.015(4.92%) |
Mkt cap ! $47.42M | |||
| Open | High | Low | Value | Volume |
| 30.0¢ | 31.0¢ | 28.5¢ | $191.2K | 643.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 53694 | 29.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 51000 | 2 |
View Market Depth
| Last trade - 15.36pm 26/06/2025 (20 minute delay) ? |
| PIQ (ASX) Chart |